-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PD-1 Silent PSMA Or PSCA Targeted CAR-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PD-1 Silent PSMA Or PSCA Targeted CAR-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PD-1 Silent PSMA...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AT-101 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-101 in Diffuse Large B-Cell Lymphoma Drug Details: AT-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986218 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986218 in Non-Small Cell Lung Cancer Drug Details: BMS-986218...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMS-906 in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMS-906 in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OMS-906 in Paroxysmal Nocturnal Hemoglobinuria Drug Details: OMS-906 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Sodium Phosphate in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Sodium Phosphate in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Sodium Phosphate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMS-906 in Kidney Disease (Nephropathy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMS-906 in Kidney Disease (Nephropathy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OMS-906 in Kidney Disease (Nephropathy) Drug Details: OMS-906 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Obinutuzumab in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obinutuzumab in Mantle Cell Lymphoma Drug Details: Obinutuzumab (Gazyva, Gazyvaro,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST-617 in Chemotherapy Induced Oral Mucositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST-617 in Chemotherapy Induced Oral Mucositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST-617 in Chemotherapy Induced Oral Mucositis Drug Details: ST-617 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBT-369 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBT-369 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBT-369 in Primary Mediastinal B-Cell Lymphoma Drug Details: BBT-369 is...